Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967181 | 1.00 | SLC6A9 (0.40) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| SCHEMBL13223389 | 1.00 | SLC6A9 (0.40) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| SCHEMBL1133814 | 1.00 | — | — | |
| SCHEMBL14100030 | 1.00 | SLC6A9 (0.40) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| SCHEMBL7744888 | 1.00 | SLC6A9 (0.40) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| SCHEMBL24220960 | 1.00 | SLC6A9 (0.40) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| SCHEMBL7539880 | 0.92 | KDM4E (0.39) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| SCHEMBL14511367 | 0.92 | KDM4E (0.39) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| Propane SCHEMBL11849460 | 0.92 | KDM4E (0.39) | SLC6A9TP53RAB9AKDM4EMEN1 | |
| SCHEMBL1785534 | 0.92 | ALDH1A1 (0.41) | SLC6A9KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705315-A1 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | Merck Sharp & Dohme LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4665410-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| WO-2024228936-A1 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | MERCK SHARP & DOHME LLC (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024206577-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-10-03 | — | — | WO | claimed |
| EP-4426360-A1 | METHODS OF TREATING CANCER | Fusion Pharmaceuticals Inc. (CA) | 2024-09-11 | — | — | EP | claimed |
| WO-2024173876-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2023050008-A9 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2024-07-25 | — | — | WO | claimed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| US-20050175543-A1 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | BRACCO IMAGING S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| EP-1509254-A1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | Bracco Imaging S.p.A. (IT) | 2005-03-02 | — | — | EP | claimed |
| US-20050008573-A1 | Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri) | BRACCO IMAGING S.P.A. (IT) | 2005-01-13 | — | — | US | claimed |
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | claimed |
| WO-2003103722-A1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | BRACCO IMAGING S.P.A. (IT) | 2003-12-18 | — | — | WO | claimed |
| EP-1369134-A1 | New agents for magnetic imaging method | Bracco Imaging S.p.A. (IT) | 2003-12-10 | — | — | EP | claimed |
| EP-0743283-B1 | Recovery of gadolinium and its complexing agents from aqueous solutions containing their complexes | BRACCO IMAGING SPA (IT) | 2001-06-27 | — | — | EP | claimed |
| US-5595714-A | Recovery of gadolinium and its complexing agents from aqueous solutions containing their complexes | DIBRA S.P.A. (IT) | 1997-01-21 | — | — | US | claimed |
| EP-0743283-A2 | Recovery of gadolinium and its complexing agents from aqueous solutions containing their complexes | BRACCO S.p.A. (IT) | 1996-11-20 | — | — | EP | claimed |
| WO-1995031444-A1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 1995-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | H1-2, H1-0, H1-3 | SLC6A9 3108/4885TP53 3932/4885RAB9A 2322/4885 |
| US-20050175543-A1 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | SLC7A5, SLC2A9, SLC2A1 | SLC6A9 97/4885TP53 398/4885RAB9A 2841/4885 |
| US-20050008573-A1 | Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri) | CCKAR, SSTR3, SSTR1 | SLC6A9 825/4885TP53 1891/4885RAB9A 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.